HOME >> BIOLOGY >> NEWS
'Good' bacteria could save patients from infection infection by deadlier ones

Jerusalem Can it be that the stress on the use of antiseptics and antibiotics in hospitals is actually putting patients at a greater risk of suffering fatal bacterial infection?

Yes, argues Mark Spigelman, a visiting professor at the Sanford F. Kuvin Center for the Study of Infectious and Tropical Diseases at the Hebrew University of Jerusalem's Faculty of Medicine. Prof. Spigelman points to a recent BBC report on the poor record of bacterial infections in patients (the worst in Europe) in British public hospitals, especially involving the deadly MRSA (methacillin resistant staphylococcus aureus) bacteria. Despite being around for 40 years, these bacteria are still basically found only in hospitals. The question Spigelman asks is why?

Spigelman, who is also a visiting professor at University College London, argues in an article appearing in the current online edition of the Annals of the Royal College of Surgeons of England that the stress on antibiotics and scrubbing with antiseptic soap may actually open an avenue for the more virulent forms of bacteria to attack patients. This is so because these "preventive" measures destroy beneficial bacteria, while at the same time the more "nasty" bacteria are often able to survive by adapting themselves to the pharmacological means used against them.

Since different strains of bacteria do not generally occupy the same surfaces, it would be better, argues Spigelman, to allow the harmless or "good" bacteria to live in the hospital environment, thus creating a kind of natural protection against the deadlier strains.

To test his hypothesis, Spigelman suggests experimenting with antibiotic-free hospitals in which harmless bacteria would be free to exist and there would be no environmental "incentive" for the more virulent strains to develop. Any patients needing antibiotics would be transferred to hospitals where they are in use. Doctors in the antibiotic-free hospitals would not enter and tre
'"/>

Contact: Jerry Barach
jerryb@savion.huji.ac.il
972-2-588-2904
The Hebrew University of Jerusalem
2-Nov-2005


Page: 1 2

Related biology news :

1. In limiting life span, study finds booming bacteria innocent
2. Cornell scientists link E. coli bacteria to Crohns disease
3. Pets could be source of multiresistant bacteria infections in humans, MU researchers investigate
4. Researchers watch antibiotics, bacteria meet at atomic level
5. A new plant-bacterial symbiotic mechanism promising
6. Piecing together the cyanobacteria puzzle
7. New research shows vaginal bacteria vary among healthy women, need customized treatment
8. New way to target and kill antibiotic-resistant bacteria found
9. UCF professor finds bacterial pathogen may be key to understanding cancer development
10. Helping chlorine-eating bacteria clean up toxic waste
11. Researchers discover acquired DNA key to certain bacterial infection

Post Your Comments:
(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - handyem ... centralized around the incorporation of handyem,s HPC-150 portable ... laboratory, the Mo-POD™. This unprecedented model of mobile ... Conference at the Pennsylvania ... June 15 th to 18 th ...
(Date:6/16/2015)... , June 16, 2015 Fingerprint Cards ... fingerprint sensors in the company,s portfolio from one of its ... planned to mainly take place during the third quarter 2015. ... Asia . Jörgen Lantto, CEO of ...   the   growing interest from smartphone OEMs in integrating ...
(Date:6/15/2015)... June 16, 2015 According to ... by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, ... 2020" published by MarketsandMarkets, The Natural Language Processing Market ... CAGR of 18.4% for the forecast period 2015-2020. ... 46 F igures spread   through 155 P ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech ... surgical instruments in Orthopedics, announced today the acquisition of Turner Medical, Inc ... provider of surgical instruments to the Spine Industry. The acquisition of Turner Medical ...
(Date:7/1/2015)... , July 1, 2015   Decision ... frequently cited advantages of Otezla are its oral ... profile, as reported by surveyed rheumatologists. Otezla was ... for the treatment of active psoriatic arthritis in ... current standard of care includes conventional oral treatments ...
(Date:7/1/2015)... ALTO, Calif. , July 1, 2015 /PRNewswire/ ... focused on the development of groundbreaking drugs to ... (ALS), announced today that Robert G. Miller ... Center at Sutter Health,s California Pacific Medical Center ... The ALS Association for $1.5 million to help ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business plan ... lower the barriers to innovation in life sciences R&D. The Pistoia Alliance President’s Startup ... prizes of US$15,000 and a period of expert mentorship from a senior industry figure ...
Breaking Biology Technology:In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
Cached News: